BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,434,444 | +278.4% | 343,848 | +276.2% | 0.01% | +300.0% |
| Q2 2023 | $643,435 | -88.5% | 91,397 | -86.4% | 0.00% | -89.3% |
| Q1 2023 | $5,615,030 | +84.4% | 673,265 | +153.9% | 0.03% | +64.7% |
| Q4 2022 | $3,044,691 | +46.9% | 265,217 | +108.0% | 0.02% | +41.7% |
| Q1 2022 | $2,073,000 | -78.4% | 127,510 | -81.6% | 0.01% | -77.4% |
| Q4 2021 | $9,610,000 | -43.3% | 693,830 | -41.2% | 0.05% | -51.4% |
| Q3 2021 | $16,961,000 | +87.4% | 1,180,297 | +106.2% | 0.11% | +73.0% |
| Q2 2021 | $9,049,000 | +16.9% | 572,378 | -44.9% | 0.06% | -3.1% |
| Q4 2020 | $7,740,000 | +7488.2% | 1,038,874 | +2814.4% | 0.06% | +3150.0% |
| Q3 2019 | $102,000 | -79.4% | 35,646 | -72.6% | 0.00% | -85.7% |
| Q2 2019 | $494,000 | +384.3% | 130,300 | +942.0% | 0.01% | +366.7% |
| Q1 2019 | $102,000 | – | 12,505 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |